Drugs
SUGEN, Inc. has completed the sale of its 5% stake in Selectide Corporation to Marion Merrell Dow, Inc. for approximately $3 million. This transaction resulted in net proceeds of approximately $1.5 million to SUGEN after repurchasing 300,760 shares of its common stock from Selectide for approximately $1.43
Drugs
Genentech, Inc. has announced that the International Trade Commission (ITC) has voted not to review the ruling by its Administrative Law Judge that Genentech's case against Novo-Nordisk and Bio-Technology General Corporation (BTG) be dismissed. The ITC took no position on the ITC Judge's findings that certain
Drugs
In 1994, the pharmaceutical industry expanded its marketing efforts to directly target consumers, with a 42 percent increase in prescription product advertising between January and September. This shift in focus is attributed to the growing awareness of personal health among the public. Companies are advertising their medications to inform consumers
Drugs
Genzyme Transgenics Corp. has announced the sale of its TSI Center for Diagnostic Products (CDP) to Intergen Company, LP, a leading manufacturer of reagents for the biopharmaceutical and diagnostics industries. The acquisition, valued at approximately $4 million in 1994 revenues, will enable Genzyme Transgenics to focus on its core business:
Drugs
Genentech, a leading international biotechnology company, and Scios Nova, a biopharmaceutical company, have entered into a collaboration agreement to develop and commercialize Scios Nova's Auriculin (anaritide) for the treatment of acute renal failure (ARF). The partnership aims to leverage Genentech's expertise in clinical development and marketing
Pharmaceutical industry
Zeneca, an international bioscience company, and Salick Health Care, a leading US provider of disease-specific health care services to patients with cancer and other complex, chronic illnesses, have entered into a definitive agreement for a strategic partnership. Under the terms of the agreement, Zeneca will purchase a 50% interest in
Pharmaceutical industry
Genica Pharmaceuticals Corp., a closely held biotechnology company specializing in developing diagnostics for neurological diseases and disorders, is merging with Athena Neurosciences Inc., a research-based pharmaceutical company developing therapeutic and diagnostic products for neurological diseases and disorders. The acquisition will result in Genica stockholders receiving up to 3,450,000
Pharmaceutical industry
The US Food and Drug Administration (FDA) has announced a significant change to its regulations regarding pediatric drug labeling. The new rules, which take effect immediately, will allow companies to publish information about drug dosages for children without conducting full-scale clinical testing in those 16 and under. This move aims
Pharmaceutical industry
Zynaxis, Inc. and Genta Incorporated have signed a research and licensing agreement to develop conjugates using Zynaxis' proprietary Zyn-Linker technology and oligonucleotides from Genta. The agreement aims to enhance the uptake and biological activity of Genta's proprietary oligonucleotides. If the results are positive, the companies will proceed
Pharmaceutical industry
The failure of healthcare reform in September 1994 led to a surge in drug prices, with prescription medications rising 0.6% in October, driving up the overall medical care price index by 0.6%. According to the U.S. Bureau of Labor Statistics, medical care prices increased more than overall
Pharmaceutical industry
San Leandro, CA-based MDL Information Systems Inc., the leading supplier of chemical information management systems, and SmithKline Beecham Pharmaceuticals have announced a multimillion dollar contract that grants SmithKline Beecham unrestricted, worldwide use of MDL's client-server product, ISIS. The agreement establishes ISIS as a major component of SmithKline'
Pharmaceutical industry
Ciba-Geigy Limited, through a wholly owned subsidiary, has commenced a tender offer to purchase 11,860,467 shares of Chiron Corp.'s common stock, representing approximately 37.3% of Chiron's outstanding shares. The offer is conditioned upon the tender of 11,860,467 shares, regulatory approvals, and
